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Introduction: B7 homolog 1 (B7-H1; aka programmed cell death 
1 ligand 1) is a negative costimulatory molecule that is associated 
with poor prognosis in many tumor types. Given the poor prognosis 
and the limited treatments available for mesothelioma, we decided 
to examine B7-H1 expression and its association with survival in 
patients with mesothelioma.
Methods: Expression of B7-H1 was determined in 106 patients 
using a mouse monoclonal antihuman B7-H1 (clone 5H1-A3) anti-
body with immunohistochemistry. Positive expression was defined as 
≥5% positively stained cells. Clinicopathologic features and survival 
were compared between B7-H1-positive and B7-H1-negative groups.
Results: Malignant mesotheliomas of 42 patients (40%) expressed 
B7-H1. Patients with B7-H1-postive tumors were less likely to be 
offered or undergo therapeutic surgery (p = 0.03). All sarcomatoid 
mesotheliomas except one desmoplastic subtype expressed B7-H1. 
Survival was significantly decreased for patients whose tumors 
expressed B7-H1 (5 months median, 2–9.5 months interquartile 
range) compared with those whose tumors did not (14.5 months, 
9.25–19 months; p < 0.0001). In a multivariate model, B7-H1 expres-
sion and sarcomatoid mesothelioma remained significantly associ-
ated with worse survival (risk ratio 1.71, 95% confidence interval 
1.03–2.78 [p = 0.04] and risk ratio 2.18, 1.08–4.23 [p = 0.03], 
respectively).
Conclusions: B7-H1 is expressed in a substantial proportion of 
malignant pleural mesotheliomas and is associated with poor sur-
vival. Almost all malignant pleural mesotheliomas with sarcomatoid 
differentiation expressed B7-H1. The expression of B7-H1 may have 
important therapeutic implications for the management of malignant 
pleural mesothelioma.
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Malignant pleural mesothelioma (MPM) is an inexorably progressive malignancy that is almost universally fatal. 
There are approximately 1.05 cases per 100,000 persons in 
the United States,1 and the incidence continues to rise in many 
countries around the world.2 The immune system is capable 
of mounting a tumor-specific response to mesothelioma,3 and 
lymphocytic infiltration of mesotheliomas has been associated 
with improved survival.4 B7 homolog 1 (B7-H1; also known 
as programmed cell death 1 ligand 1) is a negative costimula-
tory molecule that is constitutively expressed on macrophage-
lineage cells and inhibits T-lymphocyte activation by binding 
to programmed cell death 1 (PD-1) receptor.5 Many human 
tumors aberrantly express B7-H1, and such expression has 
been associated with poor prognosis. Given the poor progno-
sis of mesothelioma and the limited treatment options avail-
able, we examined B7-H1 expression in MPM in a cohort 
with long-term follow-up to determine the effects of B7-H1 
expression on survival.
MATERIALS AND METHODS
Patient Selection
Patients treated at Mayo Clinic in Rochester, MN and 
diagnosed with MPM between January 1, 1987, and December 
31, 2003, with adequate tissue samples were included in this 
study. The adequacy of samples for inclusion was determined 
by a pathologist who was blinded to clinical outcomes (Y.M.S.). 
Tissue used for analysis was obtained through surgical biopsy 
of suspicious pleural lesions, pleurectomy or extrapleural pneu-
monectomy. A thoracic pathologist (A.C.R.) who was blinded 
to B7-H1 status and clinical information independently con-
firmed the diagnosis of MPM. All cases were classified accord-
ing to the current World Health Organization classification as 
epithelioid, biphasic, or sarcomatoid type.6 As desmoplastic 
mesotheliomas are accepted as a subtype of aggressive sarco-
matoid mesothelioma, the two cases in our series were included 
in the sarcomatoid group for analysis.6 Cases without a sup-
portive immunohistochemical staining pattern were excluded 
from the study. Clinical demographics and outcome informa-
tion were obtained by a retrospective chart review. This study 
was approved by the Mayo Clinic Institutional Review Board.
Immunohistochemistry
Paraffin-embedded, formalin-fixed tissue blocks were 
cut at 5 μm and deparaffinized in xylene and rehydrated in 
a graded series of ethanol. Antigen retrieval was performed 
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by heating tissue sections in Target Retrieval Solution pH 6.0 
(Dako #S1699, Carpinteria, CA) to 121°C using a Digital 
Decloaking Chamber (Biocare Medical, Walnut Creek, CA) 
cooled to 90°C and incubated for an additional 5 minutes 
before opening the Decloaking Chamber. Sections were 
washed in running distilled H
2
0 for 5 minutes and then incu-
bated for 5 minutes in Wash Buffer (Dako #S3006) before 
being placed on the Autostainer Plus (Dako) for the follow-
ing protocol using a CSA II kit (Dako #K1497). Sections 
were blocked for endogenous peroxidase for 5 minutes using 
Endogenous Blocking Solution washed in wash buffer fol-
lowed by incubation for 60 minutes in mouse monoclonal 
antihuman B7-H1 (clone 5H1-A3; as described and validated 
previously)7 diluted 1:300 with antibody diluent with back-
ground reducing components. Sections were washed in wash 
buffer and incubated 15 minutes in horse radish peroxidase-
labeled antimouse immunoglobulins washed with wash buf-
fer and incubated for 15 minutes in amplification reagent. 
Sections were then washed with wash buffer and incubated 
for 15 minutes in anti- fluorescein isothiocyanate horse rad-
ish peroxidase, washed and visualized in 3, 3′-diaminoben-
zidine for 8 minutes. Sections were washed with distilled 
H
2
0, counterstained with hematoxylin, dehydrated in ethanol, 
and cleared in xylene. A coverslip was placed with perma-
nent mounting media. The percent of B7-H1 expression was 
scored for each sample by a pathologist (Y.M.S.). Cases with 
less than 5% expression were considered negative, as per pre-
vious studies.8–10
Statistical Analysis
Summary statistics were used to describe the clinico-
pathologic data. Clinicopathologic differences between B7-H1-
positive and B7-H1-negative groups were compared with a χ2 
test. Overall survival was determined from the date of diagno-
sis to the date of death or last follow-up with the Kaplan-Meier 
method. Patients alive at the time of last follow-up were cen-
sored. Survival comparisons were made with the log-rank test. 
The associations of B7-H1 expression in the tumor cells with 
outcome were assessed with Cox proportional hazards regres-
sion models in a univariate fashion and after adjusting for any 
factor with a p value less than or equal to 0.2 in a multivariate 
model. JMP 9.0.1 (SAS Institute Inc. Cary, NC) was used for 
statistical analysis. All tests were two sided and a p value less 
than 0.05 was considered statistically significant.
RESULTS
Patient Follow-Up
One-hundred six patients were included in this study, 
and 104 patients had died at the time of last follow-up. Of the 
two patients whose deaths were not confirmed, one pursued 
care closer to home because of no evidence of recurrent dis-
ease after 10 years, and the other returned to his native country 
and was lost to follow-up after surgical care.
B7-H1 Expression
Malignant pleural mesothelioma of 42 patients (40%) 
expressed B7-H1 (Fig. 1). Of the patients who expressed 
B7-H1, the median percent of B7-H1 positive neoplastic cells 
was 35% (10–70% interquartile range). Although in most 
cases B7-H1 expression was cytoplasmic (n = 18, 43%), in 
many cases there was cytoplasmic and membranous staining 
(n = 14, 33%). Exclusive membranous staining for B7-H1 
was less common (n = 10, 24%). There were no significant 
differences in gender, age, decade of diagnosis, or lympho-
cytic infiltration between B7-H1 positive and negative tumors; 
however, patients with B7-H1 positive tumors were less likely 
to undergo therapeutic surgery primarily because of extent of 
disease (p = 0.03; Table 1). In addition, all sarcomatoid meso-
theliomas besides a single desmoplastic subtype were in the 
B7-H1-positive group. Conversely, there were fewer epitheli-
oid mesotheliomas in the B7-H1-positive group (n = 14, 33% 
of the B7-H1-positive group) than the B7-H1-negative group 
(n = 54, 84%; p < 0.0001 of the B7-H1 negative group).
Three patients had multiple samples taken at the same 
time for review. All three cases demonstrated concordant 
B7-H1 expression in regards to its presence or absence. Two 
samples from 1 patient did not have any B7-H1 expression, 
and the degree of B7-H1 expression in the two samples varied 
from 5% to 90% in 1 patient and 10–30% in another. In our 
cohort, there was 1 patient from the 1980s, 57 patients from 
the 1990s, and 48 patients from the 2000s. There was no dif-
ference in the number of patients with B7-H1 expression by 
decade (p = 0.57).
Association of B7-H1 Expression with Survival
Survival was significantly shorter for patients with 
B7-H1 expression (5 months median, 2–9.5 months interquar-
tile range) than those without B7-H1 expression (14.5 months, 
9.25–19 months; p < 0.0001; Fig. 2). Among patients with epi-
thelioid histology, there was longer survival in patients whose 
tumors did not express B7-H1 (14 months, 9–18 months) 
than in patients whose tumors expressed B7-H1 (6 months, 
2–17 months), but this difference was not statistically signifi-
cant (p = 0.10). There was no difference in survival between 
patients with cytoplasmic B7-H1 expression and patients 
with any membranous expression (p = 0.44). In a multivari-
ate model, B7-H1 expression remained significantly associ-
ated with worse survival after adjusting for age, histology, and 
therapeutic surgical intervention (risk ratio 1.71, 95% confi-
dence interval 1.03–2.78; p = 0.04). Sarcomatoid histology 
also remained significantly associated with worse survival 
(risk ratio 2.18, 1.08–4.23; p = 0.03).
DISCUSSION
We found that B7-H1 is expressed in 40% of MPM in a 
relatively large cohort with almost complete follow-up. B7-H1 
expression was correlated with decreased survival, even after 
adjusting for multiple factors. Importantly, every case of MPM 
with sarcomatoid differentiation expressed B7-H1 with the 
exception of a single case with a desmoplastic subtype. These 
findings suggest that agents that target B7-H1 or its receptor 
(PD-1) warrant exploration for the treatment of mesothelioma, 
especially for patients with sarcomatoid mesothelioma.
Immune surveillance is a critical component of tumor 
growth control11 and tumor-infiltrating CD3+ and CD8+ 
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FIGURE 1.  B7-H1-positive malignant mesothelioma, sarcomatoid type: neoplastic spindle cells are growing in a haphazard 
and tumefactive pattern (A, A insert). The neoplastic cells show diffuse and strong membranous and cytoplasmic expression of 
B7-H1 (B, B insert). B7-H1-positive malignant mesothelioma, epithelioid type: neoplastic epithelioid cells are invading into adi-
pose tissue (C, C insert). The neoplastic cells are strongly and diffusely positive for B7-H1 with a predominant cytoplasmic and 
focal membranous staining pattern (D, D insert). B7-H1-negative malignant mesothelioma, biphasic type: neoplastic spindle 
cells are growing in a tumefactive pattern. Islands of neoplastic epithelioid cells are also present (E, E insert). The neoplastic cells 
are negative for B7-H1 (F, F insert). Magnification x 100 (A-F), × 400 (A-F inserts).
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lymphocytes have been associated with improved survival 
in many tumor types including MPM.12 Antitumor immu-
nity is modulated by a combination of positive and nega-
tive costimulatory signals to ensure appropriate physiologic 
immune responses and self-tolerance without tissue dam-
age. Tumors co-opt many of the co-inhibitory signals used to 
dampen immune responses. Recently, a strategy of inhibit-
ing cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), 
a co-inhibitory signal, has proven effective for the treatment 
metastatic malignant melanoma.13 Although there are durable 
responses to CTLA-4 inhibitors, treatment is relatively toxic 
and CTLA-4 expression is not specific to the tumor micro-
environment. Notably, the strategy of CTLA-4 inhibition in 
mesothelioma is currently under investigation and has shown 
some encouraging results.14
B7-H1 is another co-inhibitory molecule and its expres-
sion is normally limited to macrophage-lineage cells; how-
ever, it has been detected on many tumors. B7-H1 is the ligand 
for programmed cell death 1 (PD-1) that is expressed on T 
cells. B7-H1 activation of PD-1 inhibits effector molecules 
involved with CD3+ T cell signaling,15–17 blunts lymphocyte 
activation18 and promotes immune tolerance.19 Furthermore, 
tumor-specific immune responses are impaired by PD-1-
B7-H1 interactions.20,21 Tumor expression of B7-H1 is a poor 
prognostic feature in esophageal carcinoma,22 gastric carci-
noma,23 hepatocellular carcinoma,24 pancreatic carcinoma,25 
renal cell carcinoma,26–29 and ovarian carcinoma.30 The degree 
of B7-H1 expression we detected in mesothelioma is similar to 
that reported in a clinical trial for malignant melanoma,31 but 
higher than that reported for squamous cell carcinoma of the 
lung.32 Recently, targeting the PD-1/B7-H1 axis in many early 
phase clinical trials has demonstrated durable responses in 
patients with various solid tumors.8,31,33–36 Given the degree of 
expression of B7-H1 in mesothelioma, especially for patients 
with sarcomatoid differentiation, and its association with poor 
survival, we believe that there is a potential role for targeting 
PD-1/B7-H1 interactions in this malignancy.
In this study, we evaluated patient samples that were 
fixed in formalin and embedded in paraffin. In renal cell car-
cinoma, the proportion of patients with B7-H1 expression has 
been higher in studies that use fresh-frozen tissue instead of for-
malin-fixed paraffin-embedded.10,27,28 However, given the rarity 
of MPM and the often rather small amount of tissue that was 
needed for diagnostic purposes in its entirety, it was not fea-
sible for us to conduct as large of a study with fresh-frozen tis-
sue. Regardless, we may have underestimated the incidence of 
B7-H1 expression in MPM and our results should be prospec-
tively validated using fresh-frozen tissue. In addition, we used 
strict criteria for the inclusion of cases for this analysis as the 
diagnosis of MPM has been improved by the use of immuno-
histochemistry in more recent times than in previous decades. 
Although this limited our sample size, we confidently excluded 
from our analysis other malignancies that spread to the pleura.
CONCLUSION
B7-H1 is expressed in a substantial proportion of MPM 
and is associated with poor survival. Almost all MPMwith sar-
comatoid differentiation expressed B7-H1. The expression of 
B7-H1 may have important therapeutic implications for the 
management of MPM.
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TABLE 1.  Comparison of Clinicopathologic Factors by 
Tumor B7-H1 Expression
B7-H1+ B7-H1− P Value
42 (40%) 64 (60%)
Gender 0.72
  Male 35 (83%) 55 (86%)
  Female 7 (17%) 9 (14%)
Age (years; median,  
interquartile range)
68 (59–75) 65 (58–73) 0.19
Decade of Diagnosis 0.57
  1980s 0 (0%) 1 (2%)
  1990s 22 (52%) 35 (55%)
  2000s 20 (48%) 28 (43%)
Subtype <0.0001
  Epithelial 14 (33%) 54 (84%)
  Sarcomatoid 16 (38%) 1 (2%)
  Biphasic 12 (29%) 9 (14%)
Lymphocytic infiltration 0.36
  Yes 38 (90%) 54 (84%)
  No 4 (10%) 10 (16%)
Surgical treatment 0.03
  Yes 7 (17%) 23 (36%)
  No 35 (83%) 41 (64%)
The results of the univariate analysis are presented in the “P value” column.
FIGURE 2.  Survival in mesothelioma by B7-H1 expression. 
The survival of 106 patients with malignant pleural meso-
thelioma is shown based on B7-H1 expression. Two patients 
were censored. Median survival was 5 months (2–9.5 months 
interquartile range) for patients with B7-H1 expression and 
14.5 months (9.25–19 months interquartile range; p < 
0.0001) for those without B7-H1 expression.
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